Non-Hodgkin Lymphomas and CLL
We recommend
New Alternative in the Treatment of Diffuse Large B-cell Lymphoma
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not suitable candidates for autologous stem cell transplantation, a wide range of treatment regimens is available. Recently, the addition of polatuzumab vedotin to rituximab and bendamustine therapy has shown promising efficacy in both registration studies and real-world clinical practice.
Socio-economic Benefits of Using Obinutuzumab in 1st Line Treatment of Follicular Lymphoma
Pharmacoeconomic analyses remind us that our patients' diseases affect not only themselves or the…
FLEX – A New Predictive Model for Assessing Follicular Lymphoma Risks
Overall survival of patients with advanced-stage follicular lymphoma (FL) who experience early…
Articles on this topic
Targeted Treatment and Quality of Life in Patients with Follicular Lymphoma
The GALLIUM clinical trial evaluated chemotherapy in combination with targeted treatment using…
Polatuzumab Vedotin in the Treatment of NHL - News from the 25th EHA Congress
Polatuzumab vedotin (Polivy) is approved in the EU for the treatment of patients with…
Combined Treatment of Chronic Lymphocytic Leukemia in Frail Patients – Results from Real-World Clinical Practice
Treatment of older patients and those with chronic lymphocytic leukemia (CLL) who are not in…
Targeted Therapy for DLBCL Patients Who Cannot Undergo Bone Marrow Transplant
An international team of hemato-oncologists has been involved in testing polatuzumab vedotin…
Obinutuzumab and Early Progression of Patients with Previously Untreated Follicular Lymphoma − Analysis of Data from the GALLIUM Study
The GALLIUM study demonstrated longer progression-free survival (PFS) in patients with…
High-Dose Cyclophosphamide in Hard-to-Treat Patients with B-NHL
For hard-to-treat patients with non-Hodgkin lymphoma, cyclophosphamide administered in one or…
Prognostic Significance of Lymphopenia for Stratification of Patients with Follicular Lymphoma
The therapy of follicular lymphoma (FL) is guided by several prognostic indices, such as the…
Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL
Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a…
Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy
The authors of a study presented at the December congress of the American Society of…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- High-Dose Cyclophosphamide in Hard-to-Treat Patients with B-NHL
- Prognostic Significance of Lymphopenia for Stratification of Patients with Follicular Lymphoma
- Targeted Treatment and Quality of Life in Patients with Follicular Lymphoma
- Hodgkin´s Lymhoma – the Treatment Aproaches Development and Current Trends
- New Alternative in the Treatment of Diffuse Large B-cell Lymphoma
- Targeted Therapy for DLBCL Patients Who Cannot Undergo Bone Marrow Transplant
Journal on this topic
Related topic